Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2521-2529

  Figlin, Robert A ^a   Thompson, John A ^a   Bukowski, Ronald M ^a   Vogelzang, Nicholas J ^a   Novick, Andrew C ^a   Lange, Paul ^a   Steinberg, Gary D ^a   Belldegrun, Arie S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032784492     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2521     Document Type: Article

References (44)

1. National Institute of Health: SEER Cancer Statistics Review. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1990
2. Bassil B, Dosoretz DE, Prout GR: Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 134:450-454, 1985
3. deKernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 120:148-152, 1978
4. Golimbu M, Joshi P, Sperber A, et al: Renal cell carcinoma: Survival and prognostic factors. Urology 27:291-301, 1986
5. McNichols DW, Segura JW, DeWeerd JH: Renal cell carcinoma: Long-term survival and later recurrence. J Urol 126:17-23, 1981
6. Selli C, Hinshaw WM, Woodard BH, et al: Stratification of risk factors in renal cell carcinoma. Cancer 52:899-903, 1983
7. Bukowski RM, Novick AC: Clinical practice guidelines: Renal cell carcinoma. Cleve Clin J Med 64:SI1-SI44, 1997 (suppl 1)
8. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
9. Fisher RI, Rosenberg SA, Sznol M, et al: High-dose aldesleukin in renal cell carcinoma: Long term survival update. Cancer J Sci Am 3:S70-S72, 1997 (suppl 1)
10. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
11. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
12. Parkinson DR, Fisher RI, Rayner AA, et al: Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8:1630-1636, 1990
13. Gold PJ, Thompson JA, Markowitz DR, et al: Metastatic renal cell carcinoma: Long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am 3:S85-S91, 1997 (suppl 1)
14. Dutcher J, Logan T, Gordon M, et al: 5FU + subcutaneous (SC) interleukin-2 (IL-2) plus SC Intron (IFN) in metastatic renal cell cancer (RCC) patients: A CWG study. Proc Am Soc Clin Oncol 15:272, 1996 (abstr 725)
15. Dutcher JP, Fisher RI, Weiss G, et al: Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: Five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3:157-162, 1997
16. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11:1809-1816, 1993
17. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
18. Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3:S79-S84, 1997 (suppl 1)
19. Caligiuri MA, Murray C, Soiffer RJ, et al: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity. J Clin Oncol 9:2110-2119, 1991
20. Lissoni P: Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J Sci Am 3:S115-S120, 1997 (suppl 1)
21. Dutcher JP, Atkins M, Fisher R, et al: Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 3:S73-S78, 1997 (suppl 1)
22. Lissoni P, Barni S, Ardizzoia A, et al: A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori 79:397-400, 1993
23. Stein RC, Malkovska V, Morgan S, et al: The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 63:275-278, 1991
24. Belldegrun A, Pierce W, Kaboo R, et al: Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol 150:1384-1390, 1993
25. Fisher RI, Coltman CA, Doroshow JH, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II clinical trial. Ann Intern Med 108:518-523, 1988
26. Belldegrun A, Muul JM, Rosenberg SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity. Cancer Res 48:206-214, 1988
27. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79:1067-1075, 1987
28. Belldegrun A, Tso CL, Kaboo R, et al: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. J Immunother 19:149-161, 1996
29. Finke JH, Rayman P, Alexander J, et al: Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363-2370, 1990
30. Rosenberg SA, Schwartz S, Spiess PJ: Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alpha-interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80:1393-1397, 1988
31. Figlin R, Gitlitz B, Franklin J, et al: Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am 3:S92-S97, 1997 (suppl 1)
32. Figlin RA, Pierce WC, Kaboo R, et al: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740-745, 1997
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Bukowski RM, Sharfman W, Murthy S, et al: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 51:4199-4205, 1991
35. Kradin RL, Kurnick JT, Lazarus DS, et al: Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1:577-580, 1989
36. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. N Engl J Med 319:1676-1680, 1988
37. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 1988
38. Economou JS, Belldegrun AS, Glaspy J, et al: In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes: Results of a double gene marking trial. J Clin Invest 97:515-521, 1996
39. Mulders P, Tso CL, Pang S, et al: Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 21:170-180, 1998
40. Steger GG, Pierce WC, Figlin R, et al: Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL): Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Clin Immunol Immunopathol 72:237-247, 1994
41. Flanigan RC: Role of surgery in patients with metastatic renal cell carcinoma. Semin Urol Oncol 14:227-229, 1996
42. Walther MM, Alexander RB, Weiss GH, et al: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42:250-257, 1993
43. Rackley R, Novick A, Klein E, et al: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152:1399-1403, 1994
44. Franklin JR, Figlin R, Rauch J, et al: Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience. Semin Urol Oncol 14:230-236, 1996